menu
    • menu
    [{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Mabwell Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Mabwell Bioscience"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Eye Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TRE-515","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TRE-515","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Trethera","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Cancer Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":"14","companyTruncated":"Trethera \/ Small Business Innovation Research"}]

    Find Clinical Drug Pipeline Developments & Deals for TRE-515

    Menu

    TRE-515

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Wins $2M NIH Grant for Pediatric Neurologic Disease Development

                            Details : The funding aims to support Trethera’s clinical stage and first-in-class drug, TRE-515 dCK inhibitor, which is being evaluated for the treatment of acute disseminated encephalomyelitis.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated...

                            Details : The proceeds will be used for the preclinical development of Trethera’s first-in-class small molecule, TRE-515, an orally delivered, therapeutic engineered to inhibit dCK, for the treatment of acute disseminated encephalomyelitis, which holds the FDA O...

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 14, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-...

                            Details : The grant will fund Investigational New Drug (IND) enabling activities using TRE-515, a first-in-class deoxycytidine kinase (dCK) inhibitor, to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease with significant morbidity and mortalit...

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers...

                            Details : The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515, a first-in-class deoxycytidine kinase inhibitor, in solid tumors.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid T...

                            Details : TRE-515 is a potent and orally-bioavailable inhibitor of dCK that may have monotherapy activity against solid tumors where low expression of the de novo pathway or other metabolic changes occur creating greater sensitivity to nucleotide salvage pathway i...

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 15, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclero...

                            Details : TRE-515 is an orally delivered first-in-class dCK inhibitor, the key enzyme in the nucleoside salvage pathway. TRE-515 is twice designated an Orphan Drug by the FDA in both optic neuritis and ADEM and is currently being studied in a Phase 1 oncology tria...

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Eye Institute

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuriti...

                            Details : TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Eye Institute

                            Deal Size : $1.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association A...

                            Details : TRE-515 is an orally delivered first-in-class therapeutic selectively inhibit symptoms in experimental autoimmune encephalomyelitis (EAE) mouse models of multiple sclerosis (MS).

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity...

                            Details : TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) and currently in Phase 1 clinical trials. Trethera is currently enrolling a Phase 1 dose escalation trial to evaluate TRE-515 monotherapy in patients with various solid tumo...

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : UCLA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptom...

                            Details : TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : UCLA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth